Incidence of late stent thrombosis with bare-metal, sirolimus, and paclitaxel stents

Reviews in Cardiovascular Medicine

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Holmes Jr , David R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antiplatelet therapy; Bare metal stents; Drug eluting stents; Interventional cardiology; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; ANTITHROMBOCYTIC AGENT; PACLITAXEL; POLYMER; RAPAMYCIN; THIENO[2,3 B]PYRIDINE DERIVATIVE;

BARE METAL STENT; BLEEDING; DRUG ELUTING STENT; HUMAN; INCIDENCE; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; PATIENT COMPLIANCE; REVIEW; STENT; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

AGNOSIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; METALS; MYOCARDIAL ISCHEMIA; PACLITAXEL; PROSTHESIS FAILURE; SIROLIMUS; WORLD HEALTH;

EID: 33947611609     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Westphal SP. Concerns prompt some hospitals to pare use of drug-coated stents. Wall Street Journal. June 22, 2006:A1.
2. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
3. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-1521.
4. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705.
5. Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol. 2002;40:1567-1572.
6. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-1971.
7. Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med. 2004;5:9-15.
8. Cutlip DE, Windecker S, Mehran R, et al. Clinical endpoints in coronary stent trials: a case for standardized definitions. J Am Coll Cardiol. In press.
9. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45: 2088-2092.
10. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007; 369:667-678.
11. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
12. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-959.
13. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol. 2005;45:941-946.
14. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher register. Circulation. 2006;113:1434-1441.
15. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting stents versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355: 1093-1104.
16. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105-1113.
17. Honda Y, Fitzgerald PJ. Stent thrombosis-an issue revisited in a changing world. Circulation. 2003;108:2-5.
18. Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registty. Circulation. 1996;94:1519-1527.
19. De Servi S, Repetto S, Klugmann S, et al. Stent thrombosis: incidence and related factors in the RISE Registry (Registre Impianto Stent Endocoronarico). Catheter Cardiovasc Interv. 1999;46:13-18.
20. Schuhlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 1998;98:104-111.
21. Moussa I, Di Mario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997;29:6-12.
22. Werner GS, Gastmann O, Ferrari M, et al. Risk factors for acute and subacute stent thrombosis after high-pressure stent implantation: a study by intracoronary ultrasound. Am Heart J. 1998; 135:300-309.
23. Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation. 2003;108:43-47.
24. Serruys PW, Unger F, Sousa JE. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease [comment]. N Engl J Med. 2001;344:1117-1124.
25. Morice M-C, Serruys PW, Sousa JE, for the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
26. Weisz G, Leon MB, Holmes DR Jr, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol. 2006;47:1350-1355.
27. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362: 1093-1099.
28. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110-1115.
29. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545.
30. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation. 2004;109:487-493.
31. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
32. Tanabe K, Serruys PW, Degertekin M, et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation. 2004;109:196-200.
33. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942-1947.
34. O'Neill WW, Midei MG, Cox DA, et al. The DELIVER trial: a randomized comparison of paclitaxel-coated versus metallic stents for treatment of coronary lesions. Late-Breaking Clinical Trial Results presented at: American College of Cardiology 52nd Annual Scientific Session; March 30-April 2, 2003; Chicago, IL.